KMPHARMACEUTICAL Co.,Ltd. (KOSDAQ:225430)
South Korea
· Delayed Price · Currency is KRW 628.00
-8.00 (-1.26%)
At close: Aug 1, 2025, 3:30 PM KST
KMPHARMACEUTICAL Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 14,088 | 14,475 | 17,770 | 15,631 | 22,705 | 22,928 | Upgrade
|
| Other Revenue | - | - | - | -0 | -0 | - | Upgrade
|
| Revenue | 14,088 | 14,475 | 17,770 | 15,631 | 22,705 | 22,928 | Upgrade
|
| Revenue Growth (YoY) | -17.59% | -18.54% | 13.68% | -31.16% | -0.97% | 12.73% | Upgrade
|
| Cost of Revenue | 10,714 | 10,869 | 12,859 | 12,407 | 17,042 | 16,988 | Upgrade
|
| Gross Profit | 3,374 | 3,606 | 4,910 | 3,225 | 5,663 | 5,941 | Upgrade
|
| Selling, General & Admin | 4,860 | 4,865 | 4,976 | 3,219 | 3,948 | 4,537 | Upgrade
|
| Research & Development | 628.2 | 559.98 | 298.31 | 450.38 | 404.56 | 306.7 | Upgrade
|
| Other Operating Expenses | 82.89 | 76.4 | 59.75 | 59.04 | 59.54 | 138.13 | Upgrade
|
| Operating Expenses | 7,500 | 7,453 | 6,024 | 6,946 | 4,797 | 5,228 | Upgrade
|
| Operating Income | -4,126 | -3,848 | -1,113 | -3,722 | 866.14 | 712.32 | Upgrade
|
| Interest Expense | -588.54 | -582.34 | -613.68 | -384.49 | -173.49 | -495.16 | Upgrade
|
| Interest & Investment Income | 706.18 | 672.3 | 675.68 | 431.1 | 52.57 | 51.15 | Upgrade
|
| Currency Exchange Gain (Loss) | -4.86 | -1.59 | -6.09 | -12.15 | -15.66 | -15.23 | Upgrade
|
| Other Non Operating Income (Expenses) | -91.31 | -100.64 | 17.67 | -16.74 | -74.01 | 57.99 | Upgrade
|
| EBT Excluding Unusual Items | -4,104 | -3,860 | -1,040 | -3,704 | 655.55 | 311.07 | Upgrade
|
| Gain (Loss) on Sale of Investments | -405.23 | -389.25 | 74.79 | -61.63 | -674.13 | 15.99 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.26 | -0.21 | 10.42 | - | 6.56 | -4.66 | Upgrade
|
| Asset Writedown | - | - | -9.19 | -808.27 | -501.8 | - | Upgrade
|
| Pretax Income | -4,510 | -4,249 | -963.76 | -4,574 | -513.83 | 322.4 | Upgrade
|
| Income Tax Expense | 371.56 | 323.93 | 356.29 | -649.05 | 97.36 | -148.48 | Upgrade
|
| Net Income | -4,881 | -4,573 | -1,320 | -3,925 | -611.19 | 470.88 | Upgrade
|
| Net Income to Common | -4,881 | -4,573 | -1,320 | -3,925 | -611.19 | 470.88 | Upgrade
|
| Shares Outstanding (Basic) | 28 | 28 | 28 | 28 | 28 | 21 | Upgrade
|
| Shares Outstanding (Diluted) | 28 | 28 | 28 | 28 | 28 | 21 | Upgrade
|
| Shares Change (YoY) | -6.51% | -0.71% | 0.90% | 0.20% | 29.80% | 2.01% | Upgrade
|
| EPS (Basic) | -173.92 | -163.99 | -47.00 | -141.00 | -22.00 | 22.00 | Upgrade
|
| EPS (Diluted) | -173.92 | -163.99 | -47.00 | -141.00 | -22.00 | 22.00 | Upgrade
|
| Free Cash Flow | -1,932 | -2,401 | 1,333 | -151.02 | -97.92 | -2,828 | Upgrade
|
| Free Cash Flow Per Share | -68.83 | -86.09 | 47.48 | -5.42 | -3.52 | -132.12 | Upgrade
|
| Gross Margin | 23.95% | 24.91% | 27.63% | 20.63% | 24.94% | 25.91% | Upgrade
|
| Operating Margin | -29.29% | -26.58% | -6.26% | -23.81% | 3.82% | 3.11% | Upgrade
|
| Profit Margin | -34.65% | -31.60% | -7.43% | -25.11% | -2.69% | 2.05% | Upgrade
|
| Free Cash Flow Margin | -13.71% | -16.59% | 7.50% | -0.97% | -0.43% | -12.33% | Upgrade
|
| EBITDA | -2,835 | -2,513 | 255.73 | -2,263 | 2,308 | 1,854 | Upgrade
|
| EBITDA Margin | -20.13% | -17.36% | 1.44% | -14.47% | 10.17% | 8.09% | Upgrade
|
| D&A For EBITDA | 1,291 | 1,335 | 1,369 | 1,459 | 1,442 | 1,142 | Upgrade
|
| EBIT | -4,126 | -3,848 | -1,113 | -3,722 | 866.14 | 712.32 | Upgrade
|
| EBIT Margin | -29.29% | -26.58% | -6.26% | -23.81% | 3.82% | 3.11% | Upgrade
|
| Advertising Expenses | - | 990.45 | 470.11 | 577.67 | 700.87 | 640.13 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.